{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:37:10Z","timestamp":1760146630078,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Introduction: Variants of COVID-19 are responsible for 700 million infections and 7 million deaths worldwide. Vaccinations have high efficiency in preventing infection and secondary benefits of reducing COVID-19 hospital admissions, attenuating disease severity and duration of illness. Conflicting reports were published regarding COVID-19 among PLWH. Objective: The aim of this study was to evaluate COVID-19 morbidity, hospitalization, and the magnitude of immunological response to sequential BNT 162b2 mRNA vaccines in PLWH regarding demographic and clinical factors. Results: Our retrospective study included 784 PLWH who had at least one anti- SARS-CoV-2 antibody test between March 2021 and October 2021. Half of our patients (392) had CD4 cell counts above 500 cells\/\u00b5L, 40.2% (315) had 200 &lt; CD4 &lt; 500 cells\/\u00b5L and only 9.8% (77) had CD4 &lt; 200 cells\/\u00b5L at their last laboratory workup. The mean age was 50.2 \u00b1 12.2 years. About 90% of our patients were given at least two doses of the BNT 162b2 Pfizer vaccines; about 60% received three doses of the vaccine. About a quarter of our patients (27.6%) had COVID-19 infection. Only six patients required hospital admission. All six patients recovered from COVID-19 infection. Titers of COVID-19 antibodies were lower for patients with CD4 cell counts of less than 200 cells\/\u00b5L in the first, second, and third serological tests with statistical significance. In a multinomial logistic regression, the influence of other factors such as age, sex, and previous COVID-19 infection on first COVID-19 antibody titers was not significant. Conclusions: PLWH are responsive to COVID-19 vaccines. As was expected, patients with higher CD4 cell counts had higher titers of COVID-19 antibodies and lower hospitalization rate. Age, sex, and previous COVID-19 infection did not significantly affect antibody titers according to our study. Larger prospective studies with control groups are needed to further characterize immunologic response to COVID-19 vaccination among PLWH.<\/jats:p>","DOI":"10.3390\/v16121805","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:46:11Z","timestamp":1732164371000},"page":"1805","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 Vaccinations, Infections, and Outcomes Among 784 People Living with HIV"],"prefix":"10.3390","volume":"16","author":[{"given":"Keren","family":"Mahlab-Guri","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel"},{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Komarova","sequence":"additional","affiliation":[{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laliv","family":"Kadar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel"},{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay","family":"Nemet","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel"},{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5615-4066","authenticated-orcid":false,"given":"Ramon","family":"Cohen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel"},{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Radian-Sade","sequence":"additional","affiliation":[{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achiel","family":"Tova","sequence":"additional","affiliation":[{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Guri","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel"},{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shira","family":"Rosenberg-Bezalel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel"},{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9056-236X","authenticated-orcid":false,"given":"Daniel","family":"Elbirt","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel"},{"name":"Allergy, Clinical Immunology and AIDS Center, Kaplan Medical Center, Rehovot 7680400, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and Attenuation of COVID-19 with the BNT162b2 and mRNA-1273 Vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"Bertagnolio, S., Thwin, S.S., Silva, R., and Clinical, D.J. (2021). Features and Prognostic Factors of COVID-19 in People Living with HIV Hospitalized with Suspected or Confirmed SARS-CoV-2 Infection, WHO."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/25787489.2021.1975608","article-title":"HIV and COVID-19: Review of clinical course and outcomes","volume":"22","author":"Barbera","year":"2021","journal-title":"HIV Res. Clin. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2037069","DOI":"10.1001\/jamanetworkopen.2020.37069","article-title":"COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state","volume":"4","author":"Tesoriero","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Faiz, Z., Quazi, M.A., Vahil, N., Barrows, C.M., Ikram, H.A., Nasrullah, A., Farooq, A., Gangu, K., and Sheikh, A.B. (2023). COVID-19 and HIV: Clinical Outcomes among Hospitalized Patients in the United States. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071904"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.pvr.2019.100174","article-title":"HPV vaccination in HIV infection","volume":"8","author":"Lacey","year":"2019","journal-title":"Papillomavirus Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/infdis\/jis695","article-title":"Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya","volume":"207","author":"Irungu","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.4049\/jimmunol.1501524","article-title":"Reversible reprogramming of circulating memory T follicular helper cell function during chronic HIV infection","volume":"195","author":"Cubas","year":"2015","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liu, Y., Han, J., Li, X., Chen, D., Zhao, X., Qiu, Y., Zhang, L., Xiao, J., Li, B., and Zhao, H. (2021). COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity. Vaccines, 9.","DOI":"10.3390\/vaccines9121458"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s15010-021-01721-7","article-title":"Humoral response to SARS-CoV-2 vaccines in people living with HIV","volume":"50","author":"Noe","year":"2022","journal-title":"Infection"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofac089","DOI":"10.1093\/ofid\/ofac089","article-title":"SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center","volume":"9","author":"Tau","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Govere-Hwenje, S., Jarolimova, J., Yan, J., Khumalo, A., Zondi, G., Ngcobo, M., Wara, N.J., Zionts, D., Bogart, L.M., and Parker, R.A. (2022). Willingness to accept COVID-19 vaccination among people living with HIV in a high HIV prevalence community. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-13623-w"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/QAI.0000000000003177","article-title":"COVID-19 Vaccination and Hospitalization Among Persons Living With Diagnosed HIV in New York State","volume":"93","author":"Rosenthal","year":"2023","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zemer, V.S., Grossman, Z., Cohen, H.A., Hoshen, M., Gerstein, M., Yosef, N., Cohen, M., and Ashkenazi, S. (2022). Acceptance Rates of COVID-19 Vaccine Highlight the Need for Targeted Public Health Interventions. Vaccines, 10.","DOI":"10.3390\/vaccines10081167"},{"key":"ref_17","unstructured":"Israeli Ministry of Health (2024, August 01). Corona Virus in Israel\u2014Data (in Hebrew), Available online: https:\/\/datadashboard.health.gov.il\/portal\/dashboard\/health\/%7Cdashboard."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2095","DOI":"10.1093\/cid\/ciaa1605","article-title":"Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study","volume":"73","author":"Geretti","year":"2021","journal-title":"Clin Infect Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2215934","DOI":"10.1001\/jamanetworkopen.2022.15934","article-title":"Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States","volume":"5","author":"Coburn","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Liu, Y., Zeng, F., Meng, Y., Liu, H., and Deng, G. (2023). Correlation between CD4 T-Cell Counts and Seroconversion among COVID-19 Vaccinated Patients with HIV: A Meta-Analysis. Vaccines., 11.","DOI":"10.3390\/vaccines11040789"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1093\/cid\/ciac238","article-title":"Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count","volume":"75","author":"Antinori","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000003166","article-title":"Impaired antibody response to COVID-19 vaccination in advanced HIV infection","volume":"36","author":"Hassold","year":"2022","journal-title":"AIDS"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/QAI.0000000000003475","article-title":"COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis","volume":"97","author":"Yang","year":"2024","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s11845-022-03044-4","article-title":"Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection","volume":"192","author":"Duro","year":"2023","journal-title":"Ir. J. Med. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41564-021-01046-z","article-title":"Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults","volume":"7","author":"Schulz","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-022-00452-6","article-title":"Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy","volume":"7","author":"Brumme","year":"2022","journal-title":"npj Vaccines"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1805\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:36:23Z","timestamp":1760114183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["v16121805"],"URL":"https:\/\/doi.org\/10.3390\/v16121805","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}